4 recruiting, 1 active not recruiting, 1 not yet recruiting. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Recruiting 4, Active not recruiting 1, Not yet recruiting 1 |
Follow IgA Nephropathy (IgAN): new trials by email Literature Review of IgA Nephropathy (IgAN) trials Research Report on IgA Nephropathy (IgAN)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Jade Biosciences, Inc. | 480 | 2026-12-01 | 2026-11-03 |
| A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 340 | 2026-11-11 | 2026-11-19 |
| Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN HSK39297, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 370 | 2026-04-07 | 2026-05-28 |
| Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis Telitacicept - IgA Nephropathy (IgAN), IgAVN | Phase 3 | Not yet recruiting | Guixia Ding | 124 | 2025-08-01 | 2025-07-10 |
| A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria SC0062 strength 10mg, Placebo matched to SC0062 - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Biocity Biopharmaceutics Co., Ltd. | 360 | 2025-02-14 | 2025-02-17 |
| To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy Telitacicept 160mg, Corticosteroid, ACE Inhibitor or Angiotensin receptor antagonist - IgA Nephropathy (IgAN) | Phase 3 | Active not recruiting | The Affiliated Hospital of Xuzhou Medical University | 150 | 2024-08-01 | 2025-08-01 |
Glomerulonephritis, IGA (6) · Proteinuria (2) · Autoimmune Diseases (1) · Glomerulonephritis (1) · Immune System Diseases (1) · Kidney Diseases (1) · Nephritis (1) · Urogenital Diseases (1) · Urologic Diseases (1)
Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Male Urogenital Diseases (6) · Autoimmune Diseases (5) · Glomerulonephritis (5) · Immune System Diseases (5) · Kidney Diseases (5) · Nephritis (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Urination Disorders (2) · Urological Manifestations (2)
telitacicept (2) · Adrenal Cortex Hormones (1) · Angiotensin Receptor Antagonists (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Atrasentan (1) · Methylprednisolone (1) · Prednisolone (1)
Biocity Biopharmaceutics Co., Ltd. (1) · Guixia Ding (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Jade Biosciences, Inc. (1) · Novartis Pharmaceuticals (1) · The Affiliated Hospital of Xuzhou Medical University (1)
China (3) · United States (2) · Australia (1) · Israel (1)
Li Li, MD (1)